Skip to main content

M19-345 A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastati

NCT03821935

A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors.

Associated Conditions

Multiple Tumor Types

Principal Investigator

George Simon

Sponsor

AbbVie

The purpose of this study is to see if the study drug is safe and able to treat patients who have certain types of cancers, including solid tumors, triple negative breast cancer, pancreatic cancer, urothelial cancer, hepatocellular carcinoma, colorectal cancer, and Head and neck squamous cell carcinoma.

This study is currently enrolling.